Although many studies have proven the key roles of the CCL2–CCR2 axis in tumor progression in a variety of cancers, there are no clinically available drugs that can modulate the CCL2–CCR2 axis as anticancer agents so far. This evidence concerns the gene CCL2 and neoplasm.